REGULATORY

Ex-JPMA President Ueno Takes on New AMED Advisor Role

January 6, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Hiroaki Ueno, former president of the Japan Pharmaceutical Manufacturers Association (JPMA), has taken up a newly created post at the Japan Agency for Medical Research and Development (AMED), effective January 1. According to AMED, Ueno was named special adviser to…

To read the full story

AMED, JPMA Poised to Embed Pharma Expertise in Drug Discovery
January 20, 2026

REGULATORY

AMED Warns Projects without Japan Return May Miss Startup Funding
March 26, 2026
Japan Cabinet Approves National MCM Strategy to Boost Pandemic Response
March 25, 2026
Pharma Urges Govt Support as Iran War Shows Early Impact on Supply Chains
March 25, 2026
Japan Panel Slams MHLW’s 80% Single-IRB Target as Too Low
March 24, 2026
Ishin Proposes Macroeconomic Indexing for Healthcare as LDP Talks Resume
March 24, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste

By Ken Yoshino

Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…